Emerging Growth Conference 97
Logotype for ASP Isotopes Inc

ASP Isotopes (ASPI) Emerging Growth Conference 97 summary

Event summary combining transcript, slides, and related documents.

Logotype for ASP Isotopes Inc

Emerging Growth Conference 97 summary

28 Oct, 2026

Business strategy and technology

  • Four verticals span nuclear medicine, electronic gases, medical isotopes and nuclear energy; Quantum Leap Energy is expected to spin out and be separately listed on Nasdaq.

  • South African plants for carbon-14, silicon-28 and ytterbium-176 are built; silicon-28 is operational and progressing toward its first batch shipment.

  • ASP and laser-based quantum enrichment processes target isotope supply gaps; the speaker cited zero U.S. domestic production for the isotopes under consideration and Russia as a major supplier.

  • Noble Africa began liquid helium production; first commercial isotope shipments are targeted before year-end, with helium shipments planned for December and January.

Nuclear medicine and radiopharmacies

  • PET Labs supplies tens of thousands of nuclear medicine doses annually in South Africa; NuMed and East Coast Nuclear Pharmacy operate in the U.S.

  • Focus is on higher-value cancer-treatment isotopes, including ytterbium-176 feedstock for lutetium-177 used in Novartis’ PLUVICTO; estimated future global ytterbium and gadolinium market is $100m.

  • Global nuclear medicine market estimated at $33bn, radiopharmaceuticals at $13.5bn and commercial radiopharmacy at $6bn; market growth forecast at 8% from 2026 to 2031.

  • Plan to acquire and upgrade radiopharmacies with advanced production capabilities; target is about 10 locations in five years and 30 in 10 years.

Alpa Theranostics pipeline

  • Alpa’s VHH nanobody platform pairs diagnostic and therapeutic radioisotopes; first candidates are expected to enter patients later in 2026, with Phase I data expected in 2027.

  • Three assets are planned to enter clinical development within six to nine months; initial focus includes triple-negative breast cancer and osteosarcoma.

  • Phase I trials are planned in South Africa, with a first U.S. IND filing targeted for 2027; management said the South African path from concept to IND could take about two years.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from ASP Isotopes